Skin bleeding time for the evaluation of uremic platelet dysfunction and effect of dialysis.
BACKGROUND
In patients with chronic kidney disease (CKD) predisposition to bleeding is frequently seen due to disturbances in platelet adhesion and aggregation. Various tests have been utilized to evaluate the disturbance of hemostasis in end-stage renal disease patients. In this trial; we evaluated skin bleeding time in patients admitted to our hospital with uremic symptoms and having hemodialysis (HD) for the first time. We also examined the effects of HD and uremia on this test and investigated its effectiveness in predicting the hemorrhagic complications before implementation of invasive procedures in uremic patients.


METHODS
Twenty nine patients (13 men,16 women; mean age 59.7 ± 18.1) with CKD who presented with symptoms of uremia and treated with HD for the first time were enrolled in this trial. The skin bleeding time were measured before initiation of first hemodialysis and after the second hemodialysis session.


RESULTS
The skin bleeding time after the second dialysis was significantly shorter when compared to pre-dialysis values (p < 0.05). Correlation analysis between the skin bleeding time and urea, creatinine, hemoglobin, platelet, and bicarbonate showed no correlation.


CONCLUSIONS
Skin bleeding time could reveal the uremic platelet dysfunction and beneficial effect of dialysis in the patients who presented with uremic symptoms and treated with HD for the first time. We suggest that skin bleeding time may be an appropriate test for the evaluation of hemostasis disturbance in uremic patients and prediction of the bleeding risk before invasive procedures.
Department of Nephrology, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey. yaseminsoyoral@yahoo.com
Yasemin Usul
YU
Soyoral
Cengiz
C
Demir
Huseyin
H
Begenik
Ramazan
R
Esen
Mehmet Emin
ME
Kucukoglu
Mehmet Naci
MN
Aldemir
Davut
D
Demirkiran
Reha
R
Erkoc
D000328:Adult; D000368:Aged; D001639:Bicarbonates / Q000097:blood; D001760:Bleeding Time; D001791:Blood Platelet Disorders / Q000097:blood / Q000175:diagnosis* / Q000209:etiology; D001792:Blood Platelets / Q000502:physiology*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003404:Creatinine / Q000097:blood; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D012867:Skin / Q000098:blood supply*; D014508:Urea / Q000097:blood; D014511:Uremia / Q000097:blood* / Q000209:etiology / Q000628:therapy
D001639:Bicarbonates; D006454:Hemoglobins; D014508:Urea; D003404:Creatinine